PROGRESS IN SMALL-MOLECULE DGAT2 INHIBITORS

ADVERTISEMENT RETURN TO BOOKPREVChapterNEXTPROGRESS IN SMALL-MOLECULE DGAT2 INHIBITORSKevin J. FilipskiKevin J. FilipskiPfizer Research and Development, Cambridge, Massachusetts, U.S.A.More by Kevin J. Filipski, Kentaro FutatsugiKentaro FutatsugiPfizer Research and Development, Cambridge, Massachusetts, U.S.A.More by Kentaro Futatsugi, Robert DulleaRobert DulleaPfizer Research and Development, Cambridge, Massachusetts, U.S.A.More by Robert Dullea, Michelle R. GarnseyMichelle R. GarnseyPfizer Research and Development, Cambridge, Massachusetts, U.S.A.More by Michelle R. Garnsey, and Daniel J. SmaltzDaniel J. SmaltzPfizer Research and Development, Cambridge, Massachusetts, U.S.A.More by Daniel J. SmaltzDOI: 10.1021/mc-2024-vol59.ch05Publication Date (Web):November 18, 2024Publication HistoryPublished online18 November 2024Request reuse permissions Copyright © 2024 MEDI, Inc. Published by American Chemical Society.2024 Medicinal Chemistry ReviewsChapter 5pp 83-100Medicinal Chemistry ReviewsVol. 59ISBN13: 9781734427493eISBN: 9781734427486Chapter Views-Citations-LEARN ABOUT THESE METRICSChapter Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts. Share ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookXWeChatLinkedInRedditEmail Other access options Get e-Alerts